DrugBiological
Anti-inhibitor coagulant complex clinical trials
Also written FEIBA.
Keep track of what changes. Save the anti-inhibitor coagulant complex studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Other names
Combined with it in one product
Studies by the year they started
9 studies that test it; most in 2000 (1)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2003 | 1 |
| 2009 | 1 |
| 2016 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 7
Baxalta now part of Shire (2) · Children's Hospital Los Angeles (1) · Oregon Health and Science University (1) · Tulane University School of Medicine (1) · Skane University Hospital (1) · Emory University (1) · Northwell Health (1) · Mayo Clinic (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses anti-inhibitor coagulant complex is read from its arms, and is right about nine times in ten.
Testing it · 9
- SAFE Study: Safety of aPCC Following Emicizumab ProphylaxisRecruitingPhase 3Emory UniversityNCT04563520Written as FEIBA
- Factor VIII Inhibitor Bypass Activity (FEIBA) Versus Fresh Frozen Plasma As First Line Therapy For Bleeding After Cardiac SurgeryRecruitingPhase 2Northwell HealthNCT07032792Written as FEIBA
- FEIBA Reconstitution Volume Reduction and Faster Infusion Study (FEIBA STAR)CompletedPhase 3Baxalta now part of ShireNCT02764489Written as FEIBA
- FEIBA to Optimize Postcardiopulmonary Bypass Hemostasis in Pediatric Cardiac PatientsWithdrawnPhase 2Mayo ClinicNCT05020483Written as FEIBA
- A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on EmicizumabActive, not recruitingPhase 4Children's Hospital Los AngelesNCT04205175Written as Feiba
- Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer InhibitorCompletedPhase 3Baxalta now part of ShireNCT00851721Written as Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)
- FEIBA and Use of Blood Products in Cardiac SurgeryCompletedPhase 1Oregon Health and Science UniversityNCT02577614Written as FEIBA
- Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With InhibitorsCompletedPhase 2/3Tulane University School of MedicineNCT00221195Written as activated prothrombin complex concentrate (FEIBA)
- The FEIBA NovoSeven Comparative StudyCompletedNot applicableSkane University HospitalNCT00166309Written as FEIBA and NovoSeven
Codes
What other systems call anti-inhibitor coagulant complex · ClinicalTrials.gg INT003530
- MeSH (NLM) C065655anti-inhibitor coagulant complexConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) CS849DUN3MANTI-INHIBITOR COAGULANT COMPLEXConfirmed FDA, NLM
- RxNorm 314504One source FDA
- NCI Thesaurus C90853Anti-Inhibitor Coagulant ComplexOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C065655 | anti-inhibitor coagulant complex | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | CS849DUN3M | ANTI-INHIBITOR COAGULANT COMPLEX | Confirmed FDA, NLM |
| RxNorm | 314504 | — | One source FDA |
| NCI Thesaurus | C90853 | Anti-Inhibitor Coagulant Complex | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.